skip to Main Content
About Us

Andson Biotech was created to build, from the ground up, bioanalytical platforms to fill the void of existing sensor-technologies for advanced biomanufacturing. Our goal is to accelerate the development and improve the production of advanced therapies such that they can reach a broad patient population. Our technologies were developed to analyze three key aspects of any biomanufacturing process which relies on living cells 1) the secretome, 2) the intracellular content and 3) the cell-surface profile.

The secretome analysis system (SecrAS) was first developed with support from the National Science Foundation (NSF) Engineering Research Center (ERC) for Cell Manufacturing Technologies (CMaT) during the PhD studies of Mason Chilmonczyk (co-founder) while working under the guidance of Andrei Fedorov (co-founder). With the input of both CMaT and the greater advanced therapy ecosystem, including the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M), this technology was designed from scratch to meet the needs of modern cell and gene workflows. The intracellular analysis system (IntAS) was developed after the SecrAS to capture the biochemical state within a cell, and triple-shot analysis system (TriAS) represents the final frontier of complete cell state analysis including cell-surface profiling. Together, our process analytical technologies will provide innovative methodologies for understanding bioproduction from lab-to-market.

Mason A. Chilmonczyk, PhD
CEO and Cofounder

Mason developed the secretome analysis system (SecrAS) for his PhD dissertation at the Georgia Institute of Technology under Andrei G. Fedorov. During his postdoc, Mason served as the entrepreneurial and technical lead for the project, securing Biolocity and Georgia Research Alliance funding to support the development of the technology. Mason formally cofounded Andson Biotech with Andrei just before it was backed by the well-known accelerator, Ycombinator, for their Winter 2022 batch. Mason has served as a consultant on projects ranging from artificial intelligence cancer diagnosis to resonance-based diagnostics sensors. Before starting his PhD, Mason worked in hands on roles that have benefitted him tremendously as an engineer including a position at a sheet metal/frame shop and as a design engineer for a pharmaceutical packaging company.

Andrei G. Fedorov, PhD

Andrei is the Associate Chair for Graduate Studies, Professor and Rae S. and Frank H. Neely Chair at the Georgia Institute of Technology Woodruff School of Mechanical Engineering. His scientific training and expertise are in electrohydrodynamics, complex fluids, (bio)chemical reaction engineering, biophysics and MEMS/nanotechnology. Andrei is also co-founder of a successful start-up company, OpenCell Technologies, which commercializes electrosonic microarray technology for high efficacy biomolecule delivery and gene transfection. As a serial entrepreneur and engineering professor with 20+ years of experience, Andrei has invented numerous technologies in diverse fields from thermal management and power generation devices to bioanalytical technologies. Andrei’s bioanalytical instrumentation development includes microfabricated ion sources for mass spectrometry, scanning electrochemical and mass spectrometry nanoprobes, environmental scanning electron microscopy of biomaterials, and microfluidic devices for separation/pre-concentration of biomolecules and gene/drug delivery. Andrei has authored over 150 archival journal papers and is an inventor on over 50 issued and pending patents. Further information is available at

Scientific Advisors
Edwin Horwitz, MD, PhD

Edwin M. Horwitz, MD, PhD, is Professor in the Department of Pediatrics at Emory University School of Medicine. A board certified pediatric hematologist/oncologist, Dr. Horwitz serves as Director of Transplantation Biology and Therapeutics at Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta. Dr. Horwitz is a member of the Cancer Immunology research program at Winship Cancer Institute.

Dr. Horwitz received his MD and PhD from Indiana University in Bloomington, Indiana where he completed postdoctoral research in Biochemistry. He completed his residency in Pediatrics at Saint Louis Children’s Hospital and his fellowship in Pediatric Hematology/Oncology at Washington University School of Medicine in Saint Louis, Missouri.

Dr. Horwitz received his MD and PhD from Indiana University in Bloomington, Indiana where he completed postdoctoral research in Biochemistry. He completed his residency in Pediatrics at Saint Louis Children’s Hospital and his fellowship in Pediatric Hematology/Oncology at Washington University School of Medicine in Saint Louis, Missouri.

Kris Saha , PhD

Krishanu “Kris” Saha (he/him) is an Associate Professor of Biomedical Engineering and Medical History and Bioethics at the University of Wisconsin-Madison. He was recently named the McPherson Eye Research Institute’s Retina Research Foundation Kathryn and Latimer Murfee Chair for 2019-2022 and an AIMBE Fellow (Class of 2022). His lab is at the Wisconsin Institute for Discovery (WID). He participates on campus in the executive committees of the Stem Cell and Regenerative Medicine Center, Robert F. Holtz Center on Science and Technology Studies, and Forward Bio Institute. Before he arrived in Madison, Dr. Saha studied chemical engineering and biotechnology at Cornell University, the University of Cambridge, and the University of California, Berkeley. In 2007 he became a Society in Science: Branco-Weiss fellow in the laboratory of Professor Rudolf Jaenisch at the Whitehead Institute for Biomedical Research at MIT and in the Science and Technology Studies program at Harvard University with Professor Sheila Jasanoff in Cambridge, Massachusetts. At UW-Madison, major thrusts of his lab involve gene editing and cell engineering of human cells found in the retina, central nervous system, liver, and blood. He has published more than 80 scientific manuscripts, filed several patents, and received awards that include the National Science Foundation CAREER Award, Biomedical Engineering Society’s Rising Star Award, and Gund Harrington Scholar Award. He is the leader of the gene therapy biomanufacturing impact area of the Grainger Institute for Engineering, a member of the National Academies’ Forum on Regenerative Medicine, a co-lead for the T cell testbed within the National Science Foundation’s Center for Cell Manufacturing Technologies (CMaT) and a Co-Chair of the Steering Committee of the National Institutes for Health’s Somatic Cell Genome Editing (SCGE) Consortium.

Bruno Marques , PhD

Bruno Marques has been building and leading the Process & Product Development team at Century Therapeutics toward manufacturing and supply of adult stem cell-derived allogeneic therapies against cancer. Prior to Century, he spent 14 years developing and commercializing biopharmaceutical products at Merck and GlaxoSmithKline. At GSK, Bruno held leadership roles in process development and portfolio management, contributing to the launch of several biological products. He eventually joined GSK’s Cell & Gene Therapy platform as Director of Manufacturing Strategy in support of autologous immunotherapies. Bruno is a Chemical Engineer by training, with a PhD from Carnegie Mellon University and a BS from the Illinois Institute of Technology.

Biolocity Team

Courtney Law, PhD

John Nicosia, PhD

Manuel Kingsley

Academic Collaborators

NSF ERC for Cell Manufacturing Technologies (CMaT)

Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M)

Back To Top